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Abstract
Rationale In party circuits dexamphetamine is frequently
used in combination with alcohol. It is hypothesized that
co-administration of dexamphetamine to alcohol might
reduce the sedative effects of alcohol, but may potentiate
risk-taking behaviour.
Objectives The study was aimed at assessing the effects of
alcohol, dexamphetamine and the combination of both on
simulated driving and cognitive performance.
Method Eighteen subjects participated in a randomized,
crossover, placebo-controlled study employing four condi-
tions: 10 mg dexamphetamine, 0.8 g/kg alcohol, 10 mg
dexamphetamine + 0.8 g/kg alcohol, and placebo. Funda-
mental driving skills and risk-taking behaviour were assessed
in a driving simulator. Subjects also completed vigilance and
divided attention tasks, and subjective ratings.
Results Mean BAC levels during simulated driving were
between 0.91‰ and 0.64‰. Subjects using alcohol showed
a significantly larger mean standard deviation of lateral
position and shorter accepted gap time and distance. Use of
alcohol or dexamphetamine + alcohol was associated with a
higher frequency of red light running and collisions than
the dexamphetamine or placebo conditions. Performance of
vigilance and divided attention tasks was significantly
impaired in the alcohol condition and, to a lesser degree,
in the dexamphetamine + alcohol condition.
Conclusion Single doses of 0.8 g/kg alcohol increased risk-
taking behaviours and impaired tracking, attention and
reaction time during a 3-h period after drinking when BACs
declined from 0.9 to 0.2 mg/ml. The stimulatory effects of
co-administration of dexamphetamine 10 mg were not
sufficient to overcome the impairing effects of alcohol on
skills related to driving.
Keywords Alcohol . Dexamphetamine . Driving
performance . SDLP. Gap acceptance . Alertness
Introduction
There is substantial evidence that consumption of psycho-
active substances such as alcohol, recreative drugs and
several prescription and “over-the-counter” drugs may
endanger traffic safety (e.g. Movig et al. 2004; Ramaekers
1998). The aim of the European project Driving under the
Influence of Drugs, Alcohol and Medicines was to establish
guidelines to combat impaired driving under the influence
of drugs and/or medication. Because in party circuits,
amphetamine appears to be frequently used in combination
with high doses of alcohol, the present study concerned the
effects of a relatively high dose of alcohol in combination
with dexamphetamine on driving performance. The effects
of alcohol on driving performance are well documented,
and impaired performance has been evidenced for blood
alcohol concentrations (BAC) as low as 0.3‰, while higher
BAC values are associated with sedation and consequently
lowered vigilance, impaired lane keeping and risk-taking
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behaviour (e.g. Moskowitz and Robinson 1986). The
effects of dexamphetamine on driving performance appear
to be less clear. Epidemiological data indicated that use of
methamphetamine, which is twice as potent as dexamphet-
amine, was associated with drifting out of lane, erratic
driving, weaving, speeding, drifting off the road, increased
risk taking and high-speed collisions (Logan 1996; Logan
et al. 1998). With regard to the effects on risk-taking
behaviour, some studies have reported decreases in impul-
sive behaviours following acute doses of 10 or 20 mg
dexamphetamine (de Wit et al. 2002) and others have
shown increases in impulsive behaviours (Hurst et al. 1967;
Evenden and Ryan 1996). Concerning cognitive perfor-
mance, De Wit et al. (2002) found that 10 or 20 mg
dexamphetamine improved performance on measures of
vigilance and memory, and decreased several forms of
impulsive behaviour. These findings suggest that low doses
of dexamphetamine may improve driving ability, although
results of studies of lower oral doses dexamphetamine (e.g.
10 mg) are equivocal and subject to inter-individual
variability (Newhouse et al. 1989; Mills et al. 2001;
Holdstock and de Wit 2001).
Data concerning the effects of the combination of
dexamphetamine and alcohol on driving ability are scarce
and ambiguous. On a theoretical basis, it may be expected
that dexamphetamine may reduce sedation and impairment
of vigilance caused by alcohol, but may potentiate risk-
taking behaviour and impaired judgement.
Moderate to higher doses of alcohol may potentiate
some adverse effects of dexamphetamine, particularly
increase of heart rate and blood pressure and cardiac
arrhythmia risk (Higgins et al. 1988; Mendelson et al.
1995; Ghuran and Nolan 2000). Therefore, it was decided
that in the present study, the lowest relevant dose of
dexamphetamine (10 mg) was to be used in combination
with 0.8 g/kg alcohol. The aim of the study was to assess
the effects of 10 mg dexamphetamine, 0.8 g/kg alcohol, and
the combination of 10 mg dexamphetamine and 0.8 g/kg




Eighteen subjects participated in the study. All participants
were infrequent recreational users of alcohol and
amphetamine-like substances, had a driving licence and
had at least 2 years of driving experience. Participants were
medically screened and familiarized in the driving simula-
tor. Subjects were paid for their participation, and all
participants signed an informed consent form. The study
was approved by the medical ethics committee of the
University Medical Center Utrecht.
Study design
The study was a double-blind, placebo-controlled study for
dexamphetamine using a randomized crossover repeated
measures design. The experimental study conditions were
(1) 10 mg dexamphetamine (DEX), (2) 0.8 g/kg alcohol +
matching placebo for dexamphetamine (ALC), (3) 10 mg
dexamphetamine + 0.8 g/kg alcohol (DEX+ALC), and (4)
matching placebo for dexamphetamine (PLA). The washout
period between the study conditions was 7 days.
Procedure
One week before the first trial day, the subjects have been
trained to perform the driving task in the simulator and the
cognitive tasks. Subjects were instructed to abstain from
alcohol and/or psychoactive drugs in the 24 h prior to each
trial day and to use no more than two caffeinated drinks
from 12 h prior to each test session. After arrival on each of
the 4 trial days, subjects were screened for alcohol in breath
(Dräger Alcotest 6510), drugs in urine (Triage® 8) and pH
of urine. Subjects were questioned about sleep quality and
length, health, abstinence from alcohol/drugs and number
of caffeinated drinks within 12 h prior to the test session.
All study sessions were performed between 1400 and 2200
hours, and each subject was assessed at the same time of day,
in order to standardize for circadian influences. Participants
drove the TNO driving simulator, consisting of a BMW 316
car mock-up with original controls linked to a dedicated
graphics computer. Participants had a 180° screen, interactive
traffic, sound and a hexapod moving base. The validity to use
this driving simulator for studies concerning cognitive aspects
of driving behaviour has been established in subjects with
various degrees of hypoglycemia (Stork et al. 2007). All
scenarios for the driving simulator were developed by the
University of Groningen (Veldstra et al. 2010). The
simulated drive had a duration of 50 min and included
urban, rural and highway driving with various traffic
densities. Critical events were included at random locations.
At the start of the ride, participants were instructed to drive
as they would normally do unless instructed otherwise. To
reduce predictability of critical events, four parallel scenarios
were used.
The Cmax of 10 mg dexamphetamine is estimated to be
2.6±2.5 h after ingestion (de Wit et al. 2000). Because it
was pursued that the Tmax would cover the 50-min
simulated driving test, the best time for the simulated ride
was considered to be approximately 2 h after ingestion of
dexamphetamine. Time of ingestion of dexamphetamine
was then defined as T=0. The BAC has been titrated to be
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0.8 g/kg at T=120 min, administered in three gifts
according to the method described in De Wit et al.
(2000). All study treatments were taken with orange juice.
Each trial day tests were performed at the following
experimental times:
T=120–170 simulated driving test
T=180–200 cognitive tasks, subjective ratings
T=240–260 cognitive tasks, subjective ratings
T=300 end of study sessions
Driving performance measures
During the simulated ride, performance has been assessed by
measuring skills at a strategical level (speed), manoeuvring
level (gap acceptance, car following, reaction to traffic light
and critical situations) and control level (lateral and longitu-
dinal control). A calibration study using the identical scenario
has been performed by Veldstra et al. (2010). The driving
scenario included the following features.
Road tracking task
In this part, participants drove on a 5.9-km straight road
with a speed limit of 80 km/h and on a 4.8-km straight rural
motorway where the speed limit was100 km/h. The drive is
monotonous, and the participant is asked to drive as she/he
would normally do (no specific instruction). Performance is
assessed by measuring the standard deviation of the lateral
position (SDLP).
Car following
The participant had to respond to the speed changes of a lead
car. Performance was measured by assessing distance head-
way, which was calculated as the distance between the follow
car and the lead car (bumper to bumper) and time headway
(THW) calculated as the time interval between the two cars.
Furthermore, average, SD, and minimum of time to collision
(TTC), speed and lateral position were measured.
Gap acceptance
Gap acceptance measures the driver’s ability to safely traverse
a crossing. The parameters included to assess risk taking are
size of the accepted gap in seconds and the distance to the car
approaching the driver while traversing the crossing.
Violating traffic regulations
The violations that were assessed in the virtual driving
environment included violating the posted speed limit,
failing to give right of way, overtaking via the emergency
lane and running a red light.
Reaction to unexpected events
Three scenarios were used to measure reactions to
unexpected events: a car failing to give way, a car suddenly
pulling out of a car park and cars suddenly coming to a
standstill on the motorway. How the driver handles these
situations was assessed by measuring the deceleration and
the minimal TTC (Van der Horst 1990).
Driving on the motorway
Speed and headway are considered as general indicators of
driving style that have been linked to accident risk when
driving on a motorway with traffic. Headway choice is
measured as an indication of risky driving. The participants
are faced with several scenarios: first, the participants have
to filter into traffic to get onto the motorway, and second,
they are driving on the motorway with normal density
traffic for 15 km when suddenly the traffic comes to a
standstill, from this point on the participants are driving in
congested traffic for 10 km, the last 5 km is normal driving
again until the participants finally leave the motorway.
Normal highway driving
The participant has to drive in normal traffic density on a
two-lane motorway with a 120-km/h speed limit. Some
other (virtual) traffic participants are programmed to keep
to the exact posted speed limit, some drive below or above
the posted speed to simulate the natural situation. How the
subjects deal with this situation is assessed by measuring
the number of times they change lanes and the mean and
minimal THW the participant holds to other traffic
participants. These above measures have been shown to
be sensitive to the effects of sedative drugs (Brookhuis et
al. 2004).
Cognitive performance and subjective ratings
In addition to the above-mentioned primary outcome
variables, variables addressing vigilance and (divided)
attention were assessed in order to evaluate the effects of
alcohol and/or amphetamine. In that context, subjects
performed five cognitive tasks: (1) the critical tracking task
(CTT, Jex et al. 1966) measuring the ability to control a
displayed error signal in a first-order compensatory tracking
task; (2) divided attention task (DAT, Moskowitz 1973),
assessing the ability to divide attention between two tasks;
(3) the psychomotor vigilance task (PVT, Loh et al. 2004),
assessing the reaction time to a visual stimulus; (4) the
Psychopharmacology (2012) 222:391–399 393
VigTrack, a dual-task measuring vigilance performance
under the continuous load of a compensatory tracking task
(Valk et al. 1997) and (5) the selective attention task from
the usual field of view test (UFOV, Ball and Owsley 1992).
The sequence of the different tasks was balanced over the
subjects to minimize order effects. After the simulator ride,
subjects completed the following subjective ratings: the
Profile of Mood States (POMS, de Wit et al. 2002), Rating
Scale Mental Effort (Zijlstra 1993), Driving Quality Scale
(Brookhuis et al. 1985), and the nine-point Karolinska
Sleepiness Scale (KSS, Reyner and Horne 1998).
Analysis
All statistical analyses were conducted by means of
Statistica Data Analysis Software (StatSoft®). Treatment
effects were investigated with repeated measures
ANOVA. If the analysis of variance indicated a condition
effect, comparisons between conditions means of the
parameters were performed using planned comparison or
Tukey HSD tests. Equivalence testing of drug effects was
based on difference scores from placebo (within group)
relative to the alcohol criterion (i.e. equivalence to a
BAC of 0.8 mg/ml).
Relationships between different variables and methods
were investigated by using correlational computations
(Pearson product–moment or Spearman Rank correlation
coefficients). In all statistical tests performed, a significance
level of 0.05 was used.
Results
Subjects
Eighteen subjects were enrolled in the study. Data sets of 16
volunteers (4 female and 12 male) were available for
analysis, because one subject did not wish to continue the
study due to sickness on the first trial day and one subject
withdrew due to medical reasons not related to the study.
Mean age of the subjects was 25.7 years (range 21–37),
and mean weight was 76.1 kg (range 50.1–106.6). On
average, subjects held a driving licence for 4.3 years and
drove 5,600 km/year on average.
Blood alcohol concentration
Alcohol levels were measured in breath by the Dräger
Alcotest 6510 (Lubeck) and transformed to BAC (Table 1).
Differences between the DEX+ALC and the ALC condition
were not significant.
Dexamphetamine concentration
Prior to the simulated driving test, 10 ml blood was taken
by venipuncture to determine dexamphetamine levels.
Blood concentrations of dexamphetamine showed no
significant difference between the DEX+ALC and DEX
condition and were respectively 20.7 ng/ml (range 11.9–
39.1) and 20.8 ng/ml (range 11.8–40.7).
Driving performance
Road tracking: SD of lateral position
The SDLP was assessed during monotonous driving on a 5.9-
km straight road with a speed limit of 80 km/h and on a 4.8-
km straight motorway where the speed limit was100 km/h.
Three subjects were excluded from the analysis due to off-
road driving. Mean SDLP was 32% (4.9 cm) higher in the
alcohol condition (ALC) than in the placebo condition (PLA).
The differences between the ALC and PLA condition were
significant at 80 km/h (F1, 12=7.12; p<0.02) as well as at
100 km/h (F1, 12=6.49; p<0.03). SDLP in the ALC
condition was also higher than in the DEX and DEX+ALC
conditions, but these differences did not reach statistical
significance. Differences between DEX or DEX+ALC and
the PLA condition were not significant. Results are presented
in Table 2.
Speed
On a road with a posted speed of 50 km/h, a treatment effect
was found on average speed (F3, 36=1.92; p<0.07, trend), SD
of speed (F3, 36=3.02; p<0.04) and maximum speed (F3, 36=
3.86; p<0.02). Subjects using ALC drove with higher average
speed (56 km/h) than those using DEX or PLA (p<0.05), had
a higher SD of speed than in the PLA condition (p<0.05) and
drove with a higher maximum speed (63 km/h) than in the
Table 1 Blood alcohol concentrations (in per mill) and ranges measured at the start of the driving test (T=120), at the end of the driving test (T=170),
at the end of the first cognitive test session (T=200), at the start of the second cognitive test session (T=240) and at the end of that session (T=260)
Condition T=120 (range), ‰ T=170 (range), ‰ T=200 (range), ‰ T=240 (range), ‰ T=260 (range), ‰
DEX+ALC 0.91 (0.63–1.22) 0.64 (0.47–0.77) 0.55 (0.39–0.66) 0.35 (0.22–0.58) 0.23 (0.10–0.43)
ALC 0.85 (0.61–1.13) 0.64 (0.46–0.77) 0.57 (0.41–0.64) 0.37 (0.18–0.51) 0.26 (0.08–0.41)
DEX+ALC dexamphetamine + alcohol condition, ALC alcohol + placebo condition
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DEX and PLA conditions. A treatment effect was found for
the SD of speed when driving on a 80-km/h road (F3, 39=
4.05; p<0.01). Subjects with DEX+ALC showed a higher SD
of speed than in the other treatments (p<0.05). When driving
on the motorway with a speed limit of 100 km/h, subjects
with DEX+ALC treatment showed higher SD of speed than
in other treatment conditions (F3, 39=3.47; p<0.003).
Gap acceptance
There were two city junction gap acceptance challenges
with traffic coming from the left and right side (gap LR)
and upcoming traffic at a Y junction (gap Y). There were
no traffic lights, while road markings and a traffic sign
indicated that the other traffic had the right of way. Results
of the LR gap challenge are presented in Figs. 1 and 2. In
both gap acceptance challenges, a significant treatment
effect was found concerning accepted gap time (F3, 42=
5.13, p=0.004 and F3, 42=3.88, p=0.02, respectively) and
accepted gap distance (F3, 42=3.87, p=0.02 and F3, 42=4.41,
p=0.009, respectively). Compared with the PLA and DEX
conditions, accepted gap time and distance were significantly
shorter when subjects had used ALC (p<0.05) or DEX+ALC
(p<0.05). No significant difference was found between
DEX+ALC and ALC concerning gap distance.
Traffic lights
Some of the traffic light scenarios were set in order to
induce a dilemma for the driver, where drivers suddenly
had to stop for the red light. Drivers in the DEX+ALC and
the ALC conditions did not stop for the red traffic light in
64% and 59% of the cases, while in the DEX and PLA
conditions drivers did not stop in 30% of the cases (chi-
square=10.8496, df=3, p=0.02).
Giving right of way
Participants were driving on a road towards a normal junction
at a posted speed of 50 km/h. The driver coming from the right
has priority over the participant. A treatment effect was found
when approaching the junction where the subject had to give
way (F3, 36=5.53; p=0.003). Subjects using ALC had
significantly higher maximum speed approaching the junc-
tion than in the DEX (p<0.05), DEX+PLA (p<0.01) and
PLA (p<0.05) condition. There were two cases in which no
right of way was given, and there were no significant
differences between treatments concerning the number of
participants coming to a standstill.
Other measures of driving behaviour
No relevant or significant differences between conditions were
found concerning variables of driving behaviour when
approaching a stop sign, filtering into traffic (ramp entry
velocity, velocity when merging, THWand merging distance),
highway driving (time to line crossing), number of line
crossings, during car following scenarios (TTC, headway,
THW, speed, lateral position) and the reaction to a car suddenly
pulling out of a parking lay (max deceleration, TTC).
Accidents and dangerous actions
When encountering a traffic jam at the highway, traversing
unsignalised crossroads or filtering into the traffic, some
participants collided on a vehicle. Compared with placebo,
significantly more accidents were observed in the ALC and
the DEX+ALC conditions (F1, 13=6.06; p<0.03). In total
there were 18 collisions, with 1 collision for DEX, 6 for
DEX+ALC, 8 for ALC and 3 for the PLA condition. There
Table 2 Mean standard deviation of the lateral position (SDLP) and
its standard deviation measured during monotonous driving on roads
where the speed limit was 80 and 100 km/h respectively
DEX DEX+ALC ALC PLA
SDLP 80 km/h 17.8±5.6 17.2±5.3 20.3 ±8.1 15.4 ±2.7
SDLP 100 km/h 18.8±7.9 17.7±8.2 20.1±6.8 15.2±4.1
















Fig. 2 Gap acceptance with traffic coming from left to right side (gap














Fig. 1 Gap acceptance with traffic coming from left to right side (gap
LR): mean accepted gap time (in seconds). Whiskers denote standard
error
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were no significant differences between the DEX and PLA
conditions. In two cases, both in the ALC condition,
participants overtook a car by driving over the emergency
lane, instead of taking over via the left lane.
Cognitive tasks
The first cognitive test session was performed with mean
BACs between 0.64‰ and 0.55‰, while mean BACs
during the second session were between 0.37‰ and 0.23‰.
For each condition the mean of the results of the two test
sessions was used to perform the statistical analysis of
differences between treatments.
Divided attention task
Performance on the DAT was significantly impaired for
subjects using ALC (Table 3). Compared to the other
conditions, they showed a larger tracking error (F3, 39=
5.15; p=0.004), higher reaction time (F3, 39=4.04; p=0.01),
higher number of missed targets (F3, 39=5.05; p=0.005), a
lower number of hits (F3, 39=5.05; p=0.005), higher
number of control losses (F3, 39=6.39; p=0.001) and more
false alarms (F3, 39=4.04; p=0.01). The number of false
alarms was higher when subjects used DEX+ALC com-
pared to DEX (p<0.05). No relevant and/or significant
correlations between DAT scores and BACs or dexamphet-
amine levels in blood could be demonstrated.
Vigilance and tracking test
Subjects using ALC showed significantly impaired vigi-
lance performance compared to the other conditions. This
was signified by a larger tracking error (F3, 45=5.01; p=
0.004), longer reaction times (F3, 45=8.38, p=0.0002) and a
higher percentage of omissions (trend: F3, 45=2.55, p=
0.07). Subjects using dexamphetamine alone (DEX)
showed the best performance, although this was not
statistically significant. There were no relevant and/or
significant correlations between VigTrack scores and BACs
or dexamphetamine levels in blood.
Other cognitive tasks
The CTT and the PVT showed no significant or relevant
differences between the treatments. On the selective
attention task from the UFOV, no significant differences
between treatments were found.
Subjective rating scales
Subjects completed the subjective rating scales immediately
after ending the simulated driving test. The KSS and POMS
were also completed in the second session at T=240.
There were significant treatment effects on KSS scores
(F3, 45=6.82; p=0.0007) Subjects using dexamphetamine
alone (DEX) or in combinationwith alcohol (DEX+ALC)were
less sleepy than subjects using PLA or ALC alone (p<0.01 for
both DEX and DEX+PLA).
The POMS scores showed significant treatment
effects, indicating that subjects using DEX reported to
feel less fatigued, more energetic, more cheerful, less
depressed and more clear headed than when they had
used ALC or PLA (all differences p<0.05). Subjects
using DEX showed higher subjectively estimated driving
quality than those who used ALC (p<0.05) and showed
the lowest level of subjectively estimated mental effort
during driving (n.s.)
Adverse effects
There were no severe adverse effects and no significant
clinical or statistical differences between the different
conditions concerning adverse effects, heart rate, or blood
pressure. Continuous ECG monitoring revealed paroxysmal
supraventricular tachycardia (SVT) in two cases using the
combination of amphetamine and alcohol. Both cases of
SVT were asymptomatic and recovered spontaneously.
Table 3 Divided attention task: scores of variables during the first session (DAT 1) and second session (DAT 2) and mean BAC levels
DEX (mean±SE) DEX+ALC (mean±SE) ALC (mean±SE) PLA (mean±SE)
DAT 1—mean BAC 0.6‰
Tracking error (mm) 14.5±1.4 17.3±0.9 19.0±1.2 16.0±1.2
Reaction time (ms) 1,766±93 1,818±107 2,071±124 1,931±110
Control losses 2.6±1.3 8.4±3.9 15.0±4.2 4.4±1.8
DAT 2—mean BAC 0.3‰
Tracking error (mm) 12.3±1.4 15.3±1.0 16.3±1.3 15.1±1.3
Reaction time (ms) 1,759±111 1,776±95 1,842±84 1,863±103
Control losses 0.6±0.3 3.6±2.0 11.7±5.1 3.6±1.8
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Discussion
The aim of the present study was to assess the effects of
10 mg dexamphetamine, 0.8 g/kg alcohol, and the
combination of 10 mg dexamphetamine and 0.8 g/kg
alcohol on driving behaviour and cognitive functioning,
using a set of measures within a scenario developed to
investigate the effects of stimulants, like dexamphetamine
and/or alcohol on simulated driving performance. We found
that mean BAC levels between 0.9‰ and 0.6‰ alcohol
significantly impaired road tracking performance, which is
in agreement with literature and replicates earlier demon-
stration of alcohol-induced impairment of road tracking
performance in actual, on-the-road driving test scenarios
(Kuypers et al. 2006; Louwerens et al. 1987; Ramaekers et
al. 2000). The mean differences in SDLP between the
alcohol and placebo conditions found in the present study
are considered to be relevant in the context of traffic safety
(4.9 cm). Co-administration of dexamphetamine did not
significantly change the impairing effect of alcohol as
evidenced by the lack of statistical interaction between
dexamphetamine and alcohol. Equivalence testing demon-
strated that the 95%CI of the change in road tracking
performance (i.e. SDLP) after combined use of dexamphet-
amine and alcohol included both the 0.8 g/kg alcohol
criterion as well as the placebo reference (zero). It is
therefore considered that the clinical relevance of the
combined effects of 10 mg dexamphetamine and 0.8 g/kg
alcohol is ambiguous, which means that some individuals
may show impairment whereas others may not.
Accepted gap time and distance were significantly
shorter when subjects had used alcohol or the combina-
tion of dexamphetamine with alcohol. Shorter accepted
gap time and distance may be interpreted as indications
of increased risk taking caused by alcohol. Such
interpretation is supported by data evidencing that
alcohol increases impulsive behaviour (de Wit et al.
2000). There was no difference between the effects of
alcohol alone or alcohol + amphetamine.
Although the addition of 10 mg dexamphetamine
appeared to reduce some impairing effects of alcohol, these
effects were not significant. These findings indicate that
addition of 10 mg amphetamine may not mitigate the
effects of a relatively high dose of alcohol. We found only a
few indications for increased risk taking associated with the
combination of dexamphetamine and alcohol. The lack of
evidence of increased risk taking associated with dexam-
phetamine may be explained by the fact that due to medical
considerations, in the present study, a relatively low dose
(10 mg) of dexamphetamine was used instead of higher
doses which are known to cause risk-taking behaviour and
impaired judgement (Simons and Valk 2000). Doses of 5–
10 mg dexamphetamine are used in the US Air Force to
improve performance of fatigued pilots (Emonson and
Vanderbeek 1995) and are known to reduce the effects of
fatigue and sleep deprivation without adverse effects such as
stimulating risk-taking behaviour (Caldwell and Caldwell
1997). Therefore it is hypothesized that a dose of 10 mg
dexamphetamine might have been too low to cause
significant anti-sedative effects, impaired judgement and
stimulation of risk-taking behaviour.
It was found that participants using 10 mg dexamphet-
amine alone caused the least number of collisions and less
passing of red traffic lights, and showed the best perfor-
mance on the divided attention and vigilance tasks.
Participants using dexamphetamine alone felt less fatigued,
more energetic, more cheerful, less depressed and more
clear headed than in any other condition.
The stimulatory effects of dexamphetamine on human
performance have been widely acknowledged, and
beneficial effects on road tracking have been described
(Ramaekers et al. 2006; Kuypers and Ramaekers 2005).
However, previous research has also demonstrated that
stimulant drugs such as amphetamine can improve
tracking performance, impulse control and reaction time,
while impairing working memory and movement percep-
tion (Kuypers and Ramaekers 2005; Lamers et al. 2003;
Silber et al. 2005, 2006). Therefore, it should be
considered that although dexamphetamine may improve
some aspects of driving performance, it might have
detrimental effects in other performance domains that are
relevant to traffic safety.
It is known that in the ‘party circuit’ (e.g. dance
parties), the amphetamine doses that are used in
combination with alcohol may be much higher than the
dose used in the present study. Moreover, the effects of
the combination of alcohol and amphetamine used during
dance parties may be potentiated by sleep deprivation.
Our findings have shown that co-administration of 10 mg
dexamphetamine did not significantly change the impair-
ing effect of alcohol. Moreover, red light running and
collisions, both highly dangerous driving acts, were
observed significantly more frequent in the alcohol
condition as well as in the alcohol + dexamphetamine
condition compared to the other conditions.
Conclusion
Risk scenarios and measures employed in the present study
were very sensitive to the effects of alcohol alone and to the
combination of alcohol and dexamphetamine. These meas-
ures demonstrated that during simulated driving, single
doses of alcohol (0.8 g/kg body weight) impaired road
tracking and increased risk-taking behaviours, indicated by
shorter gap acceptance time and distance and an increase of
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red light crossings and number of collisions, and impaired
tracking, attention and reaction time during a 3-h period
after drinking when BACs declined from 0.9 to 0.2 mg/ml.
These alcoholic impairments were not affected by the co-
administration of 10 mg dexamphetamine, indicating that
the stimulatory effects of dexamphetamine were not
sufficient to overcome the impairing effects of alcohol on
skills related to driving. The lack of mitigating effects of
dexamphetamine on alcohol-induced performance impair-
ment may be of particular importance in terms of road
safety issues. The findings of the present study justify the
conclusion that individuals using alcohol, or the combina-
tion of dexamphetamine with alcohol, should not be
allowed to participate in traffic.
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